(OTIC) - Earnings & Price History

OTIC: - 2.95, $90.15M, -0.02 (-0.84%)

Sector: Healthcare - Industry: Biotechnology

Otonomy, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of diseases and disorders of the ear in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménières disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in a Phase 1 clinical safety trial for the treatment of tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.Key Statistics

Past OTIC reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-02AMC-0.9314.515.3514.214.215.8-7.49%2.11%-5.54%287.87K
2016-11-03AMC-0.9513.6513.61211.7514.65-11.76%▲13.75%0.37%207.95K
2016-03-07AMC-0.9515.8416.3816.7115.717.022.01%-5.21%-3.30%319.52K
2015-12-11-0.93
2015-11-10-0.8327.824.4624.6223.9629.30.65%▲12.92%13.65%531.81K
2015-03-18BMO-0.6438.538.6638.2937.8539.7-0.96%0.55%-0.41%111.40K

Login | Register
Friday Nov 16, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades